Actively Recruiting
Evaluating Immune Responses to One or Two Hepatitis B Revaccination Doses in High-Risk Young Adults Without Protective Antibodies
Led by National Taiwan University Hospital · Updated on 2026-10-21
240
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying young adults born after the neonatal hepatitis B vaccination program, especially those aged 20 to 33 years, to understand how many revaccination doses of hepatitis B vaccine are needed to protect high-risk individuals who lack protective hepatitis B antibodies. This study aims to provide evidence-based guidance on the appropriate number of hepatitis B vaccine doses for these young adults without hepatitis B seroprotective antibodies. Participants are divided into four groups based on their initial antibody levels and receive either one or two doses of the hepatitis B vaccine Engerix-B. The groups are defined by anti-HBs titers low concentration 2.5-10 mIUmL or extremely low concentration less than 2.5 mIUmL. Each group includes 60 participants, totaling 240. Vaccinations are given at day 0 and day 28 for the two-dose groups or only at day 0 for the one-dose groups. The study follows participants for 12 months, measuring their antibody levels at baseline, 7-10 days, 28 days, 24-28 weeks, and 48-52 weeks after vaccination. Additional questionnaires are completed during follow-up. Researchers will analyze the antibody response rates and immune response changes over time to help guide revaccination recommendations for high-risk young adults. The study is sponsored by National Taiwan University Hospital and includes healthy volunteers aged 20 to 36 years.
CONDITIONS
Brief Title
The Immune Responses After Hepatitis B Revaccination Doses in a Young Cohort
Research Team
C
CHYI-FENG JAN, MD, PHD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here